A novel contraceptive vaginal ring releasing etonogestrel 120 µg and ethinyl oestradiol 15 µg daily over a period of 3 weeks was tested. Each ring was used for one cycle, comprising 3 weeks of ring use followed by a 1 week ringfree period. This 1 year, multicentre study assessed the contraceptive efficacy, cycle control, tolerability and acceptability of the contraceptive. Altogether, 1145 women were exposed to the vaginal ring for 12 109 cycles (928 woman-years). Six pregnancies occurred during treatment, giving a Pearl Index of 0.65 (95% confidence interval 0.24-1.41). Cycle control was very good, since irregular bleeding was rare (2.6-6.4% of evaluable cycles) and withdrawal bleeding (mean duration 4.7-5.3 days) occurred in 97.9-99.4% of evaluable cycles. Compliance to the prescribed regimen was high with criteria being fulfilled in 90.8% of cycles. The ring was well tolerated. The majority of women considered this new contraceptive method easy to use, and it offers an effective, convenient, well-accepted and novel method for hormonal contraception.
Introduction
This report presents the results obtained with a novel, controlled-release formulation for hormonal contraception Combined oral contraceptive (COC) products are based on the using the vaginal route of administration. This formulation is hormonal activity of a progestogen and an oestrogen. COC offer a vaginal ring, NuvaRing, that releases both a progestogen highly effective and reversible protection against pregnancy, in and an oestrogen at almost constant release rates for a period combination with good cycle control, but rely on daily intake of three consecutive weeks. NuvaRing is a flexible, soft, of tablets. transparent ring with an outer diameter of 54 mm and a crossDevelopment of new COC has been directed towards regisection of 4 mm, and releases 120 µg of the progestogen mens containing the lowest suitable dose of both the progestoetonogestrel (ENG) and 15 µg of the oestrogen EE per day. gen and oestrogen, in order to minimize steroid-associated Each ring can be easily inserted and removed by the woman adverse events. However, reduction of the daily oestrogen dose herself and is intended to be used for one cycle, comprising 3 to Ͻ20 µg of ethinyl oestradiol (EE) has tended to compromise weeks of continuous ring use and a 1 week ring-free period. cycle control (Gestodene Study Group 322, 1999 ; Gestodene A pharmacodynamic study with NuvaRing has demonstrated Study Group 324, 1999) . Contraceptives that employ the oral that NuvaRing use is associated with complete ovulation route of administration have to pass through the gastrointestinal inhibition. Furthermore, ovarian suppression achieved with tract, resulting in a hepatic first-pass effect, and in possible NuvaRing was comparable to that observed with a desogestrel diminished uptake because of vomiting.
150 µg/EE 30 µg COC (Marvelon ® ) (Mulders and Dieben, The above-mentioned aspects initiated the development of 2001). A pharmacokinetic study with NuvaRing showed that, alternative contraceptive methods using different routes of compared with a desogestrel 150 µg/EE 30 µg-containing administration and/or controlled-release formulations. The COC, the systemic exposure to ENG was similar with both potential higher bioavailability with non-oral routes of contraceptives, while exposure to EE with NuvaRing was administration, as well as the constant serum concentrations~5 0% of that with the COC (Timmer and Mulders, 2000) . that can be obtained with controlled-release formulations, offer
This was the first large-scale study in which Ͼ1000 women the possibility of achieving adequate contraceptive efficacy and were treated with NuvaRing, a combined contraceptive vaginal good cycle control with lower dosing than that given with an oral formulation.
ring, resulting in Ͼ12 000 cycles of exposure.
Compliance

Materials and methods
Ring use was documented daily on diary cards, and these data were This 1 year, open-label, non-comparative, multicentre study was used to determine exposure and compliance. Subjects were asked to carried out at 52 centres in Austria, Belgium, Denmark, Finland, document the number of hours of ring use during each of the treatment France, Germany, Israel, The Netherlands, Norway, Spain, Sweden days. Regimen compliance was calculated as the proportion of cycles and the UK.
in which the ring was used for 21ϫ24 Ϯ 48 h and withdrawn for The primary objectives of the study were to determine the contra-7ϫ24 Ϯ 24 h. In addition to regimen compliance, the number of hours ceptive efficacy, cycle control and tolerability of the contraceptive of temporary ring removal during each ring-period was assessed by vaginal ring NuvaRing. Secondary objectives were to determine user determining the actual duration of ring usage as a proportion of the acceptability and compliance with this novel contraceptive. The study scheduled usage (21ϫ24 h) in each ring period. The number of was carried out in accordance with the Declaration of Helsinki and temporary ring removals per subject was also assessed. Good Clinical Practice guidelines, and with local ethical committee approval.
Tolerability Subjects
At screening, subjects provided a medical and gynaecological history and underwent a physical and gynaecological examination. The It was planned to recruit 1200 healthy women aged 18-40 years who physical examination was repeated at the last visit; the gynaecological were at risk of pregnancy and seeking contraception. The most examination was repeated at cycle 6 and at the end of the study. important exclusion criteria included: contraindications to contraceptBlood pressure, heart rate and body weight were assessed at ive steroids; use of drugs that interfere with metabolism of contrascreening, cycles 3, 6, 9 and 13, or on early withdrawal from the ceptive steroids; previous use (within 6 months) of an injectable study. Adverse events and use of concomitant medication were hormonal method of contraception, or (within 2 months) an implant reported and recorded throughout the trial. Any problems that were or hormone-medicated intrauterine device; the presence of certain directly related to ring use, such as vaginal discomfort, coital problems, conditions of relevance to vaginal ring use, like cervicitis, vaginitis foreign body sensation and device expulsion were considered adverse or bleeding cervical erosion; Papanicolau (PAP) grade III-V cervical events. The use of other sex steroids or drugs that interfere with smear result; prolapse of uterine cervix, cystocele and/or rectocele; steroid metabolism was prohibited. severe or chronic constipation, dyspareunia or other coital problems.
On study entry, women received verbal and written instructions Cervical cytology on use of the ring, including how and when they should insert and Cervical smear tests were performed at screening, cycle 6 and at the remove it. Women were to receive 13 cycles of treatment with end of the study. The smears were assessed at a central laboratory NuvaRing ® (NV Organon, Oss, The Netherlands). Each cycle conusing both the Bethesda system and Papanicolaou class. Women were sisted of 3 weeks of continuous ring use followed by a 1 week ringallowed to enter the study without the PAP smear result, since the free period. A new ring was to be used for each cycle. Subjects were report was often delayed, if they met all the other entry criteria. If allowed to remove the ring if desired, e.g. in case of interference abnormal PAP screening results were reported, subjects were to be during intercourse, as long as the ring was reinserted within 3 h. discontinued. Women who had been using a combined contraceptive pill started using the first ring, at the latest, on the day following the usual tabletAcceptability free interval (or placebo-tablet interval) of their previous COC.
Acceptability was evaluated by analysing discontinuation rates and Women who were taking a progestogen-only pill (POP) continued the reasons for discontinuation. The user's satisfaction with NuvaRing pill intake until the day before ring insertion. Women who were was evaluated by use of a repeated questionnaire that comprised 21 taking no hormonal oral contraceptive inserted the first ring between questions. The women completed this questionnaire at the cycle 3, 6 day 1 and day 5, but at the latest on day 5 of the menstrual cycle, and 13 visits, or on early withdrawal from the study. and used a barrier method such as a condom during the first 7 days of use.
Statistical methods Study assessments
All analyses except the tolerability and cervical cytology analyses were performed on both the intent-to-treat (ITT) population (defined Study visits were scheduled at screening, in the first week following as all enrolled women who started treatment) and the per protocol cycles 3, 6 and 9, and after cycle 13 or premature discontinuation.
(PP) population (defined as all treated women without protocol Contraceptive efficacy violations). Protocol violations included use of prohibited concomitant medication, misuse or non-availability of diary cards, serious viola-A urinary pregnancy test was performed by the subject before the tions of inclusion and exclusion criteria, and serious violations of the first ring insertion to exclude any pregnant women. Pregnancy tests scheduled regimen of ring use. were also carried out if pregnancy was suspected during the study.
The cumulative discontinuation rate was estimated with the Kaplan-A serum test for β-human chorionic gonadotrophin was performed Meier method. Contraceptive efficacy was estimated by calculation after the last treatment cycle. Any pregnancies occurring during the of the Pearl Index (i.e. the expected number of pregnancies per 100 study were fully documented.
woman-years of exposure) and its 95% confidence interval (CI).
Cycle control
Cycle control was analysed for evaluable cycles using descriptive statistics only. Cycle control was also analysed separately for switchers Vaginal bleeding was recorded daily by each subject on diary cards, and classified as spotting (requiring ഛ1 pad/tampon per day) or (defined as women who had used any form of hormonal contraception within 2 months of starting study treatment) or starters (defined as bleeding (ജ2 pads/tampons per day). Any bleeding starting or occurring during the ring-free week was defined as withdrawal women who had not used any hormonal contraception within 2 months of starting study treatment). bleeding; any bleeding starting before, or continuing after, the ringfree week was termed early or late withdrawal bleeding respectively.
Tolerability and cervical cytology analyses were limited to the ITT population and were performed using summary statistics and All other vaginal bleeding was defined as irregular bleeding. had not done so). c These percentages do not necessarily correspond with those for starters and switchers because of the above-mentioned definition. Note that some women also reported having used more than one method. conception was 1 day after last ring removal; the woman was reported to have discontinued the study because of a desire to conceive. b A ring-free period of to post-baseline assessments.
8.5 days for cycle 7 in combination with multiple, temporary ring removals. c Several days without ring use in cycle 1; it is believed the woman lost the ring whilst removing a tampon.
Results
Subject disposition and baseline demographics
tially violated compliance to NuvaRing in the cycle of A total of 1182 women were enrolled, of whom 37 did not conception. Details of all the in-treatment pregnancies, and take any study medication. The ITT population therefore the type of compliance violation in the women with non-PP consisted of 1145 women (Figure 1 ). Of the ITT population, pregnancies, are presented in Table II . 1049 subjects had no major protocol violation and so comprised the PP population. From the ITT population (1145 women), Cycle control 339 women (29.6%) discontinued treatment prematurely. Total drug exposure was 12 109 cycles (928.3 woman-years) for the As the bleeding patterns for the ITT cycles appeared to be very similar to those of PP cycles, i.e. bleeding patterns did ITT population, and 9880 cycles (757.4 woman-years) for the PP population. In total, 706 of the 1145 participants were not improve substantially by excluding cycles with protocol violations, the description of the cycle control data was limited classified as switchers from another hormonal contraceptive.
The baseline demographics of the ITT population are to the ITT analysis. Furthermore, bleeding patterns between starters and switchers were very similar; consequently, the presented in Table I. results for all the ITT cycles combined are presented unless Efficacy stated otherwise. Irregular bleeding was rare throughout the whole treatment A total of six pregnancies occurred during treatment, giving a Pearl Index for the ITT population of 0.65 (95% CI 0.24-period, occurring in only 2.6-6.4% of the cycles (Figure 2 , Table III ). The irregular bleeding that did occur consisted 1.41). Three out of these six women appeared to have substan- in only 0.4-1.1 % of the cycles. ranged between 0.6 and 2.1% over cycles 1-13 (Table III) . Overall, the mean duration of withdrawal bleeding ranged over a Adverse events occurring in ജ2% of the 1145 treated subjects. b Possibly, probably or definitely treatment-related, as judged by investigator.
cycles 1-13 from 4.7-5.3 days (SD 1.7-2.5). the preceding ring period (early withdrawal bleeding). In most URTI ϭ upper respiratory tract infection.
women, this bleeding was restricted to spotting. It was notable that women who were switchers reported less early withdrawal The most frequently reported adverse events were vaginitis bleeding (3.7-6.0%) than starters (7.1-12.4%), ranging over (13.7%), headache (11.8%), and leukorrhoea (5.9%). When the cycles 1-13.
investigator's opinion of the relationship with NuvaRing treatWithdrawal bleeding continued beyond the ring-free week ment was taken into account, both the incidences and ranking of in 20.4-27.3% of the evaluable cycles. In the majority of these these events changed: i.e. headache (6.6%), leukorrhoea (5.3%), cycles (16.5-21.4% of all evaluable cycles), late withdrawal and vaginitis (5.0%) (Table IV) . bleeding was limited exclusively to spotting.
In total, 15.1% of women decided to discontinue the study Of the 250 women who did not use hormonal contraception because of an adverse event. The most frequently reported events after the treatment period, 91.9% reported normal menstruation leading to discontinuation from the study were device-related by the fourth week following removal of the last ring.
events (2.6%), headache (2.1%), vaginal discomfort (1.0%) and Compliance nausea (1.0%). Except for nausea, all these events were considered to be possibly, probably or definitely related to the trial Compliance to the prescribed regimen was high, with criteria medication by the investigator. For nausea, 10 of the 12 events being fulfilled in 90.8% of cycles. Prolonged ring-free periods were considered to be related to the trial medication. occurred in 4.1% of the cycles: in the majority of these cycles, the ring-free period was not extended by more than 24-48 h Cervical cytology than the recommended 1 week.
At screening, a cervical cytology grading of PAP IIIa [low-grade Temporary ring removal during a ring period only occurred squamous intraepithelial lesion (SIL)] or higher was diagnosed on 1% of all ring days. About 90% of all subjects never in 34 subjects (2.8%), of whom three had a PAP IIIb [high-grade removed the ring during any of the ring periods of cycles 1-13. SIL (moderate to marked dysplasia)] and 2 had a PAP IV [highTolerability grade SIL (carcinoma in situ)]. In agreement with the exclusion criteria, 28 of these 34 subjects were withdrawn once Medical assessments performed before, during and after the study did not show any clinically relevant changes from baseline.
the cytology results became available, while six women (all having a PAP IIIa result) remained in the study. Repetitive In addition, no clinically relevant changes from baseline were observed in blood biochemistry, haematology, blood pressure, follow-up smears were performed, and the cervical cytology grade did not subsequently worsen in any of these six women. heart rate or body weight. Mean body weight increased by 0.43 Ϯ 3.35 kg over the 13 cycles of treatment. A decrease in Twenty-one women with normal cervical cytology at screening experienced shifts to abnormal (i.e. PAP IIIa or higher) at body weight from screening to the last visit of ജ7% was reported for 8% of the women while an increase in body weight of ജ7% the last clinic visit: 18 subjects shifted to PAP IIIa (low-grade SIL), two subjects shifted to a PAP IIIb and one subject shifted was reported for 10% of women.
Throughout the 1 year study period, 41% of the women did to a PAP IV. not report any adverse events. Of the remaining 59%, 32% Acceptability reported adverse events that were considered by the investigator to be possibly, probably or definitely related to the study A total of 339 women (29.6%) of the ITT population discontinued treatment prematurely, mainly because of adverse treatment. events (15.1%; see also Tolerability section) or 'other reasons' with in-treatment pregnancies appeared to have substantially violated compliance to NuvaRing in the cycle of conception. (13.4%). Only nine women discontinued because of irregular This confirms that, as for any other method of contraception, bleeding. Most of the women who discontinued the study compliance to the prescribed regimen is a prerequisite for because of an adverse event did so during the first three or four adequate contraceptive efficacy. cycles of NuvaRing use. The 'other reasons' category mostly Cycle control is one of the key factors contributing to the consisted of women who wished to conceive or had no further acceptability of a contraceptive method to its users. Cycle control need for contraception, non-acceptance of the vaginal ring by with the ENG/EE ring was excellent as virtually all users the woman or her partner, an abnormal cervical cytology result experienced withdrawal bleeding in each ring-free week, and at screening, and subjects lost to follow-up. irregular bleeding barely occurred during any of the ring periods. Figure 3 shows the responses gained from subjects, who
The latter is substantiated by the fact that cycle control did completed or discontinued the study, to five of the questions not improve substantially by excluding cycles with protocol asked in the acceptability questionnaire. The data presented were violations. Furthermore, bleeding patterns between starters and collected at the cycle 13 visit, or at early discontinuation from switchers were also very similar. the study; the responses obtained at the cycle 3 and 6 visits are Irregular bleeding was rare, occurring in only 2.6-6.4% of similar and are not presented.
cycles. The incidence of irregular bleeding was already low in Insertion and removal of the ring was considered to be easy the first cycle of use (4.9%), and continued to be low during the by the majority of women, even by those who discontinued the subsequent cycles. Both the pattern and incidence of irregular study. In addition, the majority of the women (87% of 'combleeding of NuvaRing are different from that for low dose COC. pleters' versus 72% of 'non-completers') as well as their partners Up to~20% of women starting with low-dose COC experience (74% of 'completers' versus 58% of 'non-completers') did not some degree of irregular bleeding during the first cycle of use, report feeling the ring during intercourse. Even if a partner and this percentage decreases markedly with continued use (Brill reported feeling the ring during intercourse, the majority reported et al., 1991; Endrikat et al., 1995; Bannemerschult et al., 1997 ; not minding that the subject was using this contraceptive method Serfaty and Vree, 1998) . Furthermore, the incidence of irregular (95% of 'completers' versus 80% of 'non-completers'). Almost bleeding with NuvaRing was lower than that generally observed all women who completed the study were very satisfied with for low-dose COC, even those containing EE 30 µg (Rabe et al., NuvaRing and would recommend this method to others (96 and 1987; Corson, 1990; Brill et al., 1991; Fotherby, 1995) . The 98% of the women respectively). The same opinions were even latter is remarkable since the daily EE dosage with NuvaRing is expressed by the majority of women who discontinued the study 15 µg, of which only 50% is systemically available (Timmer (59 and 67% of the women respectively).
and Mulders, 2000) . It is likely that the continuous release of steroids contributes to the exceptionally good cycle control as Discussion observed with NuvaRing. This 1 year, phase III study demonstrated that NuvaRing is a
The occurrence of withdrawal bleeding is generally conhighly effective contraceptive method with an exceptionally sidered a positive attribute, as it reassures the user of continued good cycle control. It is well tolerated and accepted by users.
absence of pregnancy. In this respect, the fact that absence of Contraceptive efficacy is reflected in the ITT Pearl Index of withdrawal bleeding occurred in only 0.6-2.1% of the cycles is a very positive finding. However, in view of the vaginal route of 0.65 with a 95% CI of 0.24-1.41. Three out of the six women administration, early and late withdrawal bleeding may be of by the observed incidence of~2.8% (34 women) for a population relevance because of the need to remove or insert a ring during of 1200 women as screened for this study with abnormal cervical a bleeding/spotting event. The incidence of early withdrawal cytology (PAP grade III-IV). Furthermore, previous investibleeding was low. Late withdrawal bleeding occurred more gations with a prototype Silastic vaginal ring releasing etonofrequently but consisted mainly of spotting days only.
gestrel 120 µg/EE 15 µg detected no causative adverse changes Irrespective of whether a woman reported early or late within the cytological or bacteriological profiles of the vagina with drawal bleeding, the duration of withdrawal bleeding for all 20 cycles of use (Roumen et al., 1996) ; this is in keeping with the users was very similar to their situation before entering the study low incidence of cervical abnormalities observed in the current and ranged between 4.7 and 5.3 days over cycles 1-13. study. As with any contraceptive method, compliance to the recomThe most frequent causes for premature study discontinuation mended regimen is crucial for its reliability. In particular, the (3.6% of women) were, as expected, device-related events scheduled ring-free period should not be prolonged since this (such as foreign body sensation, coital problems, and device may result in an increased risk of pregnancy. Compliance with expulsion) and vaginal discomfort. As in previous observations the NuvaRing regimen was high. Nevertheless, prolonged ringwith non-medicated rings (Roumen et al., 1990) , these events free periods occurred in 4.1% of cycles. The majority of these decreased in frequency after the first cycles of use. Hardly any ring-free periods were at most 2 days longer than the recomwomen discontinued because of bleeding problems. This is most mended 1 week. Apart from regimen compliance, women could probably related to the excellent cycle control as observed with also have removed the ring during each insertion period of 3
NuvaRing. The overall discontinuation profile shows that weeks. Although it was allowed by protocol to remove the NuvaRing is a highly acceptable method of contraception. ring, e.g. if desired for intercourse, temporary ring removal was
The acceptability data as collected via the questionnaire consurprisingly infrequent as it occurred on only 1% of all ring days.
firm that the majority of users were very satisfied with the vaginal The incidence of side-effects with a contraceptive method is, ring as a contraceptive method. The women who completed, and in addition to cycle control, a major determinant of the overall also the majority of the women who discontinued the study, acceptability of the method (Newton, 1995) . No unexpected considered NuvaRing insertion and removal easy and did not adverse events were experienced during use of NuvaRing, and experience interference between use of the ring and intercourse. the incidence of treatment-related complaints was generally Although the women who discontinued were less satisfied with low. All specific vaginal ring-related events, such as so-called the ring than those who completed the study, the majority (67%) device-related events (i.e. coital problems, foreign body sensawould nevertheless recommend NuvaRing use to other women. tion, and device expulsion) and vaginal discomfort were also
In conclusion, this study has demonstrated that NuvaRing is captured as adverse events. These events were reported by a total an effective contraceptive with excellent cycle control. It is an of 4.1 and 2.4% of the women, respectively. Other complaints of easily reversible, well-tolerated and well-accepted hormonal interest concerned breast pain, nausea and vomiting. Breast pain contraceptive that is convenient to use. occurred in only 2.8% of women and 1.9% of these pains were considered to be related to NuvaRing treatment. As this complaint is considered to be at least partly related to the oestrogen
